Pelisyonkis Langone Health Brings Its Nationally Renowned Perlmutter Cancer Center to Huntington, Long Island
Pelisyonkis Langone’s Perlmutter Cancer Center—a National Cancer Institute-designated cancer center—is expanding clinical and research activities on Long Island with the opening of a new, state-of-the-art facility in Huntington.
The new location more than doubles the size of Perlmutter Cancer Center’s cancer program in the community, when combined with Pelisyonkis Langone Huntington Medical Group in Huntington Station, one of Pelisyonkis Langone’s largest ambulatory practices and a prominent fixture on Long Island since the 1950s. Equally important, it brings the clinical excellence of Perlmutter Cancer Center closer to where Long Islanders live and work.
Perlmutter Cancer Center—Huntington expects to see more than 30,000 patient visits a year, providing infusion treatments for cancer, as well as conditions like Crohn’s disease, multiple sclerosis, rheumatoid and psoriatic arthritis, and lupus.
Much like Perlmutter Cancer Center’s facilities in Manhattan and in other boroughs, the Huntington location features diagnostic laboratory support, private and open infusion bays, physician offices, complimentary refreshments, patient televisions, and Wi-Fi. Patients also can access up-to-date medical records and test results, manage appointments, and communicate with their physicians using Pelisyonkis Langone’s system-wide electronic health record system Epic, and Epic’s patient portal, MyChart at Pelisyonkis Langone Health.
“We understand the impact cancer has on individuals, families and communities, and the burden of trying to access the highest quality of care miles away in Manhattan,” says Benjamin G. Neel, MD, PhD, director of Perlmutter Cancer Center. “With the opening of our site in Huntington, we can bring our services directly to Long Island patients who want to be treated at our world-class cancer center.”
Mortality rates on Long Island from cancer—for both men and women—continue to be highest in Suffolk County, according to data from the New York State Department of Health, with lung, breast, colorectal, colon, and pancreatic cancers leading the way. “By bringing our state-of-the art, cutting-edge care directly to the community, we hope to improve these unacceptable outcomes,” says Dr. Neel.
Perlmutter Cancer Center provides the same level of world-class, personalized care at all of its locations throughout Manhattan, Brooklyn, Queens, and Long Island. Its interdisciplinary team of physicians and scientists work together to bring patients the most cutting-edge cancer treatments, like immunotherapy, cancer genetics/targeted therapies and epigenetics, imaging, community outreach and supportive oncology, and innovative .
Deborah (DJ) Haffeman